Show simple item record

dc.contributor.authorNahon, Kimberly J.
dc.contributor.authorMartínez Téllez, Borja Manuel
dc.contributor.authorRuiz Ruiz, Jonatan
dc.identifier.citationNahon, K. J., Doornink, F., Straat, M. E., Botani, K., Martinez-Tellez, B., Abreu-Vieira, G., ... & van Velden, F. H. (2018). Effect of sitagliptin on energy metabolism and brown adipose tissue in overweight individuals with prediabetes: a randomised placebo-controlled trial. Diabetologia, 61(11), 2386-2397.es_ES
dc.description.abstractThe aim of this study was to evaluate the effect of sitagliptin on glucose tolerance, plasma lipids, energy expenditure and metabolism of brown adipose tissue (BAT), white adipose tissue (WAT) and skeletal muscle in overweight individuals with prediabetes (impaired glucose tolerance and/or impaired fasting glucose). One participant from the sitagliptin group was excluded from analysis, due to a distribution error, leaving 29 participants for further analysis. Sitagliptin, but not placebo, lowered glucose excursion (−40%; p < 0.003) during OGTT, accompanied by an improved insulinogenic index (+38%; p < 0.003) and oral disposition index (+44%; p < 0.003). In addition, sitagliptin lowered serum concentrations of triacylglycerol (−29%) and very large (−46%), large (−35%) and medium-sized (−24%) VLDL particles (all p < 0.05). Body weight, body composition and energy expenditure did not change. In skeletal muscle, sitagliptin increased mRNA expression of PGC1β (also known as PPARGC1B) (+117%; p < 0.05), a main controller of mitochondrial oxidative energy metabolism. Although the primary endpoint of change in BAT volume and activity was not met, sitagliptin increased [18F] FDG uptake in subcutaneous WAT (sWAT; +53%; p < 0.05). Reported side effects were mild and transient and not necessarily related to the treatment. Twelve weeks of sitagliptin in overweight, Europid men with prediabetes improves glucose tolerance and lipid metabolism, as related to increased [18F] FDG uptake by sWAT, rather than BAT, and upregulation of the mitochondrial gene PGC1β in skeletal muscle. Studies on the effect of sitagliptin on preventing or delaying the progression of prediabetes into type 2 diabetes are warranted.es_ES
dc.description.sponsorshipThis work was supported in part by a research grant to PCNR fromthe Investigator Initiated Studies Programof Merck Sharp&Dohme Corp (IIS no. 51292). PCNR is an Established Investigator of the Dutch Heart Foundation (grant 2009T038). MRB is supported by a Dutch Diabetes Research Foundation Fellowship (grant 2015.81.1808). This collaboration project is also supported in part by the Ministry of Economic Affairs by means of the PPP Allowance made available by the Top Sector Life Sciences & Health to stimulate public–private partnerships. BMT and JRR are supported by University of Granada, Plan Propio de Investigacion 2016, Excellence actions: Units of Excellence; Unit of Excellence on Exercise and Health (UCEES). This work was also supported by the Netherlands CardioVascular Research Initiative: ‘the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organisation for Health Research and Development and the Royal Netherlands Academy of Sciences’ for the GENIUS-II project ‘Generating the best evidence-based pharmaceutical targets for atherosclerosis’ (CVON2017-20).es_ES
dc.publisherSpringer Naturees_ES
dc.rightsAtribución 3.0 España*
dc.subjectBrown adipose tissuees_ES
dc.subjectDPP4 inhibitores_ES
dc.subjectEnergy expenditurees_ES
dc.subjectSkeletal musclees_ES
dc.subjectDiabetes riskes_ES
dc.subjectObesity es_ES
dc.titleEffect of sitagliptin on energy metabolism and brown adipose tissue in overweight individuals with prediabetes: a randomised placebo-controlled triales_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España